Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.
about
Genetics and biology of pancreatic ductal adenocarcinomaT Cells and Cancer: How Metabolism Shapes ImmunityTargeting amino acid metabolism in cancer growth and anti-tumor immune responsePD-1 and its ligands are important immune checkpoints in cancerTargeting immune checkpoints in malignant gliomaMolecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenaseThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentAn Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer CellsThe dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.Rational combinations of immunotherapeutics that target discrete pathways.Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort studyBlockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cellsStructural Study of a Flexible Active Site Loop in Human Indoleamine 2,3-Dioxygenase and Its Functional Implications.Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 InhibitorsDistinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers.Tryptophan-degrading enzymes in tumoral immune resistance.Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression- and autoimmunity-associated genes.HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets.Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Challenges and future perspectives of T cell immunotherapy in cancerEBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formationDevelopment of simultaneous analysis of tryptophan metabolites in serum and gastric juice - an investigation towards establishing a biomarker test for gastric cancer diagnosis.Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growthA Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-ChemotherapyBreast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Metabolic phenotyping for monitoring ovarian cancer patients.T and NK cells: two sides of tumor immunoevasionIn vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.Interleukin-17 and type 17 helper T cells in cancer management and research.Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patientsEmerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7.PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.
P2860
Q26765438-395DEE16-880D-4CD5-BD3B-6E88A4CC3613Q26766427-C848598B-A407-4193-8419-DAD059F2BF43Q26775425-4F2B290D-139B-4B47-9FA0-913A101B2642Q28069485-968EBD39-5791-4551-8AB6-42A20FCFC313Q28072012-0D72C3E3-06F8-4E92-81E7-047EC4EDF9EEQ28115713-1D6F36B3-7194-4E8F-A8A9-6C0EC3337503Q28241308-502E5880-494A-4AF7-8D87-3013AE0A29A2Q28547142-4A597BA2-9E71-470F-908C-1948EFDF1D21Q30317628-A22750B2-79AC-44D7-98A8-4EF4EF6EFC87Q30410002-EE760B7B-6952-4E57-AC9B-482D117BB3D5Q33606144-A402A880-C89B-468C-ACF1-19585077D29AQ33633445-E44FBD19-98D9-4467-88C7-BDC1D76597FBQ33702231-6780246E-43E8-43E7-B774-BCCC9C5F3677Q33742950-BFF15971-ABC3-4C55-8B5C-02D3CF7CE798Q34443476-38ABBAB5-0BAF-4D38-BC03-5DDA3F6A44E3Q35023537-93B13C69-9FB7-4F80-ACAB-1581E480396CQ35042385-8B3E5E26-7A10-4600-B748-A542E528EEE7Q35051622-046C625F-A1AB-46FF-93AB-CA03C44950A9Q35059964-D67D6E90-6A80-4E82-B757-24C8C216F858Q35156136-FF435078-BF2B-48B4-8E1C-A3F02B917B26Q35184110-547B3A51-BFD9-4569-8C06-724F14149BFFQ35604318-DB1A4E35-46E6-4520-9B41-726BD0CCC0F8Q35799094-130E48F8-20C0-4C18-946E-4788027FA6D0Q35843507-511BDCED-96C0-4F47-8370-7904532DD556Q35953524-4D2B1799-C6F7-4032-86F3-DFAA47616094Q35986384-76F7CF4F-2AC0-4B5E-B0E1-0C9D02FD0D2FQ36033944-C8D12A68-7666-48EB-8FFB-8441F0A06832Q36476449-594A983D-E43A-43D4-837F-CC30A4D9427AQ36635458-FA86A572-0509-4B61-B68F-FFDB678FC320Q36653524-1DD44F33-73EB-4268-8639-A7ABDF8BDB39Q36708032-72137168-84E4-47AA-8069-5416CDB64A44Q36753355-33EBD1BF-9536-473B-A61F-BC2B517D0E49Q36887747-8EF4DBF1-0B7A-4E48-87BE-1ADD55128B8EQ37031654-EF2AECAC-789C-4B16-8B3A-E08F65487FCCQ37140496-CC6EB64E-E68F-404C-AC58-3E3C9AE612EAQ37158481-AD5653E4-83A6-426E-8369-74B9D9229DEFQ37188781-599CB695-626B-41A8-9A84-26371B8C2B78Q37705021-79536F0E-6BDE-4F82-95AD-FE6500141789Q37742979-0F91B8BA-9A8A-4929-9672-3E9748570CFCQ38060734-83ED36FA-F5BE-4635-8B57-A6AD06CD9634
P2860
Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Indoleamine 2,3-dioxygenase ex ...... and immunologic perspectives.
@en
Indoleamine 2,3-dioxygenase ex ...... and immunologic perspectives.
@nl
type
label
Indoleamine 2,3-dioxygenase ex ...... and immunologic perspectives.
@en
Indoleamine 2,3-dioxygenase ex ...... and immunologic perspectives.
@nl
prefLabel
Indoleamine 2,3-dioxygenase ex ...... and immunologic perspectives.
@en
Indoleamine 2,3-dioxygenase ex ...... and immunologic perspectives.
@nl
P2093
P1476
Indoleamine 2,3-dioxygenase ex ...... and immunologic perspectives.
@en
P2093
Ciriaco A Piccirillo
Jessica Godin-Ethier
Laïla-Aïcha Hanafi
Réjean Lapointe
P304
P356
10.1158/1078-0432.CCR-11-1331
P407
P577
2011-11-08T00:00:00Z